1308384-65-7

Basic information

• Product Name: TGX-D₁
• Synonyms: TGX-D₁
• CAS NO: 1308384-65-7
• Molecular Weight: 408.5
• Mol File: 1308384-65-7.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: TGX-D₁(CAS DataBase Reference)
• NIST Chemistry Reference: TGX-D₁(1308384-65-7)
• EPA Substance Registry System: TGX-D₁(1308384-65-7)

Safety Data

• Hazardous Substances Data: 1308384-65-7(Hazardous Substances Data)

Upstream product

• 62-53-3 aniline 
• 1374310-67-4 C₁₆H₂₁N₃O₅S 
• 122-98-5 2-Anilinoethanol 
• 1173900-35-0 9-(1-hydroxyethyl)-7-methyl-2-morpholino-4H-pyrido[1,2-a]pyrimidin-4-one 
• 351002-16-9 TGX₀₆₆ 
• 663619-90-7 9-bromo-2-hydroxy-7-methyl-4H-pyrido[1,2-a]pyrimidin-4-one 
• 17282-00-7 3-bromo-5-methylpyridin-2-amine 
• 1307864-98-7 C₂₄H₂₈N₄O₄ 
• 1307865-00-4 NH₂-SL-TGX 
• 1307864-99-8 C₂₉H₃₉N₅O₄ 
• 663619-89-4 7-methyl-2-(4-morpholinyl)-9-[1-(phenylamino)ethyl]-4H-pyrido[1,2-a]pyrimidin-4-one 

Downstream Products

• 1307864-99-8 C₂₉H₃₉N₅O₄ 
• 1307865-00-4 NH₂-SL-TGX 
• 1374310-68-5 C₃₉H₅₈N₄O₄ 
• 1374310-69-6 C₂₉H₃₈N₄O₄ 

Relevant articles and documents

Prodrug strategy for PSMA-targeted delivery of TGX-221 to prostate cancer cells

TGX-221 is a potent, selective, and cell membrane permeable inhibitor of the PI3K p110β catalytic subunit. Recent studies showed that TGX-221 has antiproliferative activity against PTEN-deficient tumor cell lines including prostate cancers. The objective of this study was to develop an encapsulation system for parenterally delivering TGX-221 to the target tissue through a prostate-specific membrane aptamer (PSMAa10) with little or no side effects. In this study, PEG-PCL micelles were formulated to encapsulate the drug, and a prodrug strategy was pursued to improve the stability of the carrier system. Fluorescence imaging studies demonstrated that the cellular uptake of both drug and nanoparticles was significantly improved by targeted micelles in a PSMA positive cell line. The area under the plasma concentration time curve of the micelle formulation in nude mice was 2.27-fold greater than that of the naked drug, and the drug clearance rate was 6.16-fold slower. These findings suggest a novel formulation approach for improving site-specific drug delivery of a molecular-targeted prostate cancer treatment.